Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patients

No abstract is available for this paper.

• Publication year

  2022

• Venue

  The Pharmacogenomics Journal

• Publication date

  2022-05-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41397-022-00280-wPMID 35590072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing

  2020cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update

  2020cited by this paper
• Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests

  2019cited by this paper
• Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.

  2019cited by this paper
• Increased diagnostic and new genes identification outcome using research reanalysis of singleton exome sequencing

  2019cited by this paper
• The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later

  2019cited by this paper
• Epilepsy in adults.

  2019cited by this paper
• INTU‐related oral‐facial‐digital syndrome type VI: A confirmatory report

  2018cited by this paper
• Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group

  2018cited by this paper
• HLAscan: genotyping of the HLA region using next-generation sequencing data

  2017cited by this paper
• Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients

  2017cited by this paper
• Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

  2017cited by this paper
• Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment

  2017cited by this paper
• Recent advances in epilepsy genetics.

  2017cited by this paper
• Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test

  2016cited by this paper
• Pharmacogenomics in the clinic

  2015cited by this paper
• Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes

  2015cited by this paper
• Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing

  2014cited by this paper
• Pharmacogenomics Knowledge for Personalized Medicine

  2012cited by this paper
• Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift

  2012cited by this paper
• HLA Genotype and Carbamazepine‐Induced Cutaneous Adverse Drug Reactions: A Systematic Review

  2012cited by this paper
• Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

  2012cited by this paper
• Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

  2012cited by this paper
• Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

  2012cited by this paper
• HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

  2011cited by this paper
• Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population

  2008cited by this paper
• Comparison and predictors of rash associated with 15 antiepileptic drugs

  2007cited by this paper
• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

  2005influential reference
• A marker for Stevens–Johnson syndrome

  2004cited by this paper
• Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

  2004cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper
• Cytochromes P450 and metabolism of xenobiotics

  2001cited by this paper
• The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

  2001cited by this paper
• Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

  2001cited by this paper
• Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

  2001cited by this paper
• Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.

  1996cited by this paper
• Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes.

  1985cited by this paper
• Epilepsy in adults.

  1983cited by this paper
• Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883).

  1962cited by this paper

• Influence of age and antiepileptic comedication on lacosamide concentrations in children with epilepsy: A retrospective cohort study

  2025cites this paper
• Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities

  2022cites this paper